UOC
REGN icon

UBS O'Connor’s Regeneron Pharmaceuticals REGN Stock Holding History

UBS O'Connor’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,589
Closed -$2.86M – 394
2020
Q2 		$2.86M Buy
+4,589
New +$2.6M 0.06% 197
2013
Q3 		– Sell
-8,900
Closed -$2M – 539
2013
Q2 		$2M Buy
+8,900
New +$2.07M 0.04% 328

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS O'Connor's REGN Position: Q3 2020 in Review

UBS O'Connor sold out of Regeneron Pharmaceuticals (REGN) in Q3 2020, closing a stake of 4,589 shares — an estimated $2.86M sold.

UBS O'Connor first reported a position in REGN in Q2 2013 and held it in 2 quarters. The position peaked at $2.86M in Q2 2020. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

  • UBS O'Connor reported no remaining Regeneron Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • UBS O'Connor sold 4,589 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $2.86M.
  • UBS O'Connor first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • UBS O'Connor's Regeneron Pharmaceuticals position peaked at $2.86M in Q2 2020.
  • 907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on UBS O'Connor's 13F filing for Q3 2020, filed 12 Nov 2020.